AbbVie's $650M Volume Dips 43.87% to 154th Rank Amid Biosimilar Pressures as Next-Gen Therapies Fuel 30% Sales Growth

On September 9, 2025, , , , ranking 154th in market activity. The biopharma giant continues to navigate post-Humira challenges through extended intellectual property protections, which have delayed biosimilar competition by seven years. Skyrizi and Rinvoq, next-gen therapies, , , signaling a successful pivot away from Humira’s declining revenues.

, including FDA clearances for RINVOQ in giant cell arteritis and MAVYRET in 2025. Strategic acquisitions, such as Capstan Therapeutics, bolstered its oncology pipeline, . The company’s aggressive R&D spending, , underscores its focus on innovation amid biosimilar pressures.

The backtest results indicate that a daily-rebalanced, cross-sectional portfolio buying top 500 high-volume stocks and holding overnight would require automation or ETF proxies like SPY for practical execution. Current constraints limit such strategies to single-ticker testing, with detailed volume data available for offline analysis in tools like Python or Excel.